$VBIO Releases another major positive development. A radiation-induced intestinal injury safety study funded by the U.S. government has officially started, which not only provides a strong boost to the commercialization process of Entolimod, but also highlights its strategic value in the field of biological defense. A government contract means a stable source of funding, but the path to commercialization still faces uncertainty. Small-cap biotech stocks are notoriously volatile, making them suitable for short-term trading. The release of the early autumn topline treatment data will become a key milestone, and investors need to closely monitor its subsequent performance.
$VBIO